Department of Medicine

Kidney disease gene also has a protective mutation

African Americans have long been known to be at increased risk of kidney disease due to a dangerous genetic mutation that creates a hole in the kidney cells, but Vanderbilt researchers have now discovered a protective genetic mutation that covers the hole to eliminate the risk.

Jane Case named associate vice chair for Advanced Practice for the Department of Medicine

Jane Case, DNP, APRN-BC, has been named associate vice chair for Advanced Practice for the Department of Medicine at Vanderbilt University Medical Center.

The study team included, from left, Paula Gonzalez-Ericsson, MD, Xiaopeng Sun, Justin Balko, PharmD, PhD, and Brandie Taylor, MS. (photo by Donn Jones)

Vulnerability found in immunotherapy-resistant triple-negative breast cancer

Vanderbilt researchers have discovered a druggable target on natural killer cells that could potentially trigger a therapeutic response in patients with immunotherapy-resistant, triple-negative breast cancer.

Levi Watkins Jr., MD Lecture set for Oct. 24

The 22nd annual Levi Watkins Jr., MD Lecture will be held Tuesday, Oct. 24, at noon in 208 Light Hall.

VUMC’s new automated biobanking system can store as many as 10 million biospecimens.

Research fellowship for genetic counselors established at Vanderbilt

Vanderbilt University School of Medicine has received a grant to establish a research fellowship for genetic counselors that will prepare them to contribute more fully to the advancement of personalized medicine.

Sharon Kantanie, center, participated in the study of a drug that reduced soft-tissue flare-ups and the prevented new areas of abnormal bone formation. With her are, from left, Emily Shardelow, clinical/translational research coordinator; Sharon’s parents, Mary and Stan Kantanie; Margo Black, MSN, manager of research projects for Metabolic Bone Disorders; and Kathryn Dahir, MD, professor of Endocrinology and Diabetes. (photo by Erin O. Smith)

Drug trial shows reduced abnormal bone formation in those with fibrodysplasia ossificans progressiva

A Vanderbilt clinical trial evaluating the investigational drug garetosmab has shown that it reduced soft-tissue flare-ups significantly and prevented new areas of abnormal bone formation in patients with fibrodysplasia ossificans progressiva.

1 25 26 27 28 29 123